The Scottish Precision Medicines Industry Group (SPMIG) – set up by AstraZeneca, Lilly, Novartis and Roche – is calling on NHS Scotland to make genomic testing available for every cancer patient in the country, so they can receive drugs based on the molecular profile of their tumours, if available.
Testing would also help identify patients who may be eligible to enrol into clinical trials of precision cancer drugs, according to the group, which has just published a white paper making its case and is presenting the idea to the Scottish Cancer Conference in Edinburgh today.
